1063 patents
Page 10 of 54
Utility
Method of Controlling the Pink Color Generated During Antibody Manufacturing
6 Apr 23
The invention is a method of preventing the generation of pink color during antibody manufacturing by either preventing the reduction of antibodies during manufacturing and harvest or inhibiting the conversion of cyanocobalamin (CN-Cbl) to hydroxocobalamin (HO-Cbl) during manufacturing and harvest.
Cheng DU, Ameya Umesh BORWANKAR, Joon Chong YEE, Zhijun TAN
Filed: 8 May 18
Utility
CorrectedSubstituted Bicyclic Compounds As Farnesoid X Receptor Modulators
6 Apr 23
Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Rishikesh Narayan, Subba Reddy Bandreddy, Srinivas Jogi
Filed: 14 Feb 20
Utility
Aminopyrrolotriazines as kinase inhibitors
4 Apr 23
Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
Filed: 24 Jan 19
Utility
Substituted Quinazolinyl Compounds Useful As T Cell Activators
30 Mar 23
Upender Velaparthi, Richard E. Olson, Jayakumar Sankara Warrier, Hasibur Rahaman
Filed: 22 Dec 20
Utility
Immunomodulators
30 Mar 23
The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Kevin W. GILLMAN, Jason GOODRICH, Kenneth M. BOY, Yunhui ZHANG, Claudio MAPELLI, Michael A. POSS, Paul Michael SCOLA, David R. LANGLEY, Nicholas A. MEANWELL
Filed: 20 Apr 22
Utility
BENZO[5,6][1,4]DIOXINO[2,3-B]PYRIDINE Compounds Useful As IRAK4 Inhibitors
30 Mar 23
Lidet A. Negash, Saleem Ahmad
Filed: 2 Feb 21
Utility
SUBSTITUTED 4-AMINO-1H-IMIDAZO[4,5-c]QUINOLINE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION
30 Mar 23
Improved methods and intermediates thereof for preparing substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds are described.
Sha Lou, Adrian Ortiz, Christopher Robert Jamison, Eric M. Simmons
Filed: 22 Nov 22
Utility
Substituted Indole Compounds
30 Mar 23
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, John L. Gilmore, Tsair Shamsul Haque, Brian K. Whiteley, David R. Tortolani, Shoshana L. Posy, John E. Macor, Louis J. Lombardo, Ramesh Kumar Sistla, Anupama Kandhi Ramachandra Reddy, Subramanya Hegde, Laxman Pasunoori, Sreekantha Ratna Kumar
Filed: 21 Mar 22
Utility
Combination therapy comprising nivolumab and ipilimumab
28 Mar 23
This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody.
Yong Quan, Vikram Sadineni, Wallace Kaserer
Filed: 20 Dec 19
Utility
Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3) pyridazine-3-carboxamide
28 Mar 23
Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methy-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-methyl-d3)pyridazine-3-carboxamide.
Daniel Richard Roberts
Filed: 30 May 19
Utility
Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
28 Mar 23
The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
Michael Anthony Schmidt, Bin Zheng, Kyle Knouse, Justine deGruyter, Martin D. Eastgate, Phil Baran, William R. Ewing, Richard E. Olson, Ivar M. McDonald
Filed: 12 Apr 19
Utility
Nucleic acids encoding antagonistic CD40 monoclonal antibodies
28 Mar 23
The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains.
Aaron Yamniuk, Mary Struthers, Suzanne J. Suchard
Filed: 23 Dec 21
Utility
Combination of an LSD-1 Inhibitor and Nivolumab for Use In Treating SCLC or SQNSCLC
23 Mar 23
The present application relates generally to a lysine specific demethylase-1 (LSD-1) inhibitor, or a pharmaceutically acceptable salt thereof, and nivolumab, for use in methods for treating small cell lung cancer (SCLC) and/or squamous non-small cell lung cancer (sqNSCLC).
Ellen Filvaroff, Ida Aronchik, Tracy Chow, Eric Olson, Brian Fox, Maria Wang
Filed: 5 Mar 21
Utility
Tricyclic Sulfones As Ror Gamma Modulators
23 Mar 23
Qingjie Liu, T.G. Murali Dhar
Filed: 22 Jan 21
Utility
Control of Cell Growth Through a Temperature Feedback Loop
23 Mar 23
The present invention relates to the use of online biomass capacitance monitoring in cultures as a way to control the growth of cells through the use of a temperature control loop.
Kathryn L. ARON, Jeffrey Swanberg
Filed: 7 Nov 22
Utility
Substituted Heteroaryl Compounds Useful As T Cell Activators
23 Mar 23
Upender Velaparthi, Chetan Padmakar Darne, Richard E. Olson, Prasada Rao Jalagam, Jayakumar Sankara Warrier
Filed: 22 Dec 20
Utility
IL-10 and Uses Thereof
23 Mar 23
The present disclosure provides fusion proteins comprising an IL-10 polypeptide and a second polypeptide, e.g., an Fc polypeptide.
Shodeinde COKER, Robert F. GRAZIANO, Murali GURURAJAN, Kanstantsin V. KATLINSKI, James K. LOY, Paul E. MORIN, Brian A. POIRSON, Vanessa M. SPIRES, Zheng YANG
Filed: 5 Feb 21
Utility
Combinations of DGK Inhibitors and Checkpoint Antagonists
23 Mar 23
Provided are inhibitors of diacylglycerol kinases (DGK) and methods for treating diseases that would benefit from the stimulation of the immune system, such as cancer and infections diseases, comprising administering a DGK inhibitor in combination with an antagonist of the PD 1/PD-L 1 axis and/or an antagonist of CTLA4.
Susan WEE, Joseph L. BENC, Xinyu WANG, Upender VELAPARTHI, Louis S. CHUPAK, Chatan P. DARNE, Min DING, Robert G. GENTLES, Yazhong HUANG, Scott W. MARTIN, Ivar M. MCDONALD, Richard E. OLSON, Xiaofan ZHENG, John S. TOKARSKI, Bireshwar DASGUPTA, Manjunatha Narayana Rao KAMBLE, Raju MANNOORI, Haslbur RAHAMAN, Prasada Rao JALAGAM, Saumya ROY, Gopikishan TONUKUNURU, Sivasudar VELAIAH, Jayakumar Sankara WARRIER, Kotha Rathnakar REDDY, Thiruvenkadam RAJA, Denise GRUNENFELDER, Michael WICHROSKI
Filed: 18 Dec 20
Utility
Optimization of Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof
16 Mar 23
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1).
Nils LONBERG, Mohan SRINIVASAN
Filed: 2 May 22
Utility
Biomarkers for Nanoparticle Compositions
16 Mar 23
The present invention provides methods and compositions for treating a hyperplasia (such as cancer, restenosis, or pulmonary hypertension) by administering a composition comprising nanoparticles that comprise an mTOR inhibitor (such as a limus drug) and an albumin based upon the status of an mTOR-activating aberration.
Neil P. DESAI
Filed: 11 Aug 22